From Systems to Synthetic Biology:

quantitative understandig for rational engineering

 A novel live biotherapeutic platform for treating human lung diseases

 Our platform is based on attenuated lung bacteria able to expose antigens or deliver therapeutic agents in the lung in a controlled, local and continuous manner. It allows engineering of multiple genetic circuits to specifically target and deliver payloads.

 Infectious diseases

 Chronic obstructive

pulmonary disease

 Infectious diseases

 Cystic Fibrosis

 Infectious diseases

 Asthma

 Lung Cancer

 Publications by scientific team

LoxTnSeq: random transposon insertions combined with cre/lox recombination and counterselection to generate large random genome reductions.

An engineered Mycoplasma pneumoniae to fight Staphylococcus aureus.

Engineering a genome-reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo

Lox'd in translation: contradictions in the nomenclature surrounding common lox-site mutants and their implications in experiments

A RAGE Based Strategy for the Genome Engineering of the Human Respiratory Pathogen Mycoplasma pneumoniae

Mycoplasma pneumoniae Genome Editing Based on Oligo Recombineering and Cas9-Mediated Counterselection

CReasPy-Cloning: A Method for Simultaneous Cloning and Engineering of Megabase-Sized Genomes in Yeast Using the CRISPR-Cas9 System

SynMyco transposon: engineering transposon vectors for efficient transformation of minimal genomes

 Pulmobiotics

 A novel live biotherapeutic platform

for treating human lung diseases.